Hepion Pharmaceuticals Begins Wind-Down Activities in ASCEND-NASH P-IIb Study
Shots: Hepion has begun wind-down activities of ASCEND-NASH
Oncternal Therapeutics Reports First Patient Dosing in Fourth Cohort of P-I/II Study of ONCT-534 for the Treatment of R/R mCRPC
Shots: Oncternal Therapeutics announces first patient dosing in the fourth cohort...
Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Di...
Shots: Cerevel reports results from the
Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers
Shots: The P-I study assesses the safety, tolerability and PK/PD of VENT-02 (oral)...
Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis
Shots: Artiva has dosed the first patient with AlloNK (AB-101) in
